Pharmacological and clinical properties of curcumin

Christopher S Beevers1
Shile Huang2

1Department of Pharmacology, Ross University School of Medicine, Picard-Portsmouth, Commonwealth of Dominica; 2Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, LA, USA

Abstract: The polyphenol natural product curcumin has been the subject of numerous studies over the past decades, which have identified and characterized the compound’s pharmacokinetic, pharmacodynamic, and clinical pharmacological properties. In in vitro and in vivo model systems, curcumin displays potent pharmacological effects, by targeting many critical cellular factors, through a diverse array of mechanisms of action. Despite this tremendous molecular versatility, however, the clinical application of curcumin remains limited due to poor pharmacokinetic characteristics in human beings. The current trend is to develop and utilize unique delivery systems, chemical derivatives, and chemical analogs to circumvent these pharmacological obstacles, in order to optimize the conditions for curcumin as a chemopreventive and chemotherapeutic agent in diseases such as cancer, diabetes, obesity, Alzheimer’s disease, and inflammatory disorders. The present work seeks to review recent studies in the basic pharmacological principles and potential clinical applications of curcumin.

Keywords: curcumin, pharmacological properties, signal transduction, cellular targets, cancer, inflammation

Introduction

Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione] (Figure 1) is a major chemical component of turmeric power, produced from the rhizome of the plant Curcuma longa. Pharmacologically, curcumin has been used as a traditional medicinal agent in Ayurvedic medicine for ∼6000 years. The pharmacokinetic, pharmacodynamic, and clinical pharmacological properties of curcumin have been extensively studied over the past six decades (∼3600 citations in Entrez-PubMed as of the writing of this review). These studies have demonstrated that curcumin functions as an antioxidant, anti-inflammatory, and anti-atherosclerotic; inhibits scarring, cataract, and gallstone formation; promotes wound healing and muscle regeneration; prevents liver injury and kidney toxicity; and exerts medicinal benefits against psoriasis, diabetes, multiple sclerosis, Alzheimer’s, HIV disease, septic shock, cardiovascular disease, lung fibrosis, arthritis, and inflammatory bowel disease. Recently, curcumin has garnered interest as a potential anticancer agent, for both chemopreventive and chemotherapeutic purposes. In vitro cell culture and in vivo animal studies have suggested that curcumin may be able to treat numerous types of cancer, including breast cancer, colon cancer, kidney cancer, liver cancer, leukemia, basal cell carcinoma, prostate cancer, rhabdomyosarcoma, and melanoma. Curcumin can effectively inhibit almost every major stage of carcinogenesis, including transformation, initiation, promotion, invasion, angiogenesis, and metastasis.
This review seeks to present evidence from the most recent studies in the field that suggest possible new attractive targets for curcumin; shed a greater light of confirmation on past identified targets of the agent; demonstrate novel ways of exploiting and overcoming the pharmacokinetic challenges presented by the parent compound; further elucidate the therapeutic, preventive, and/or diagnostic utility of curcumin in classically identified pathologies; and suggest the use of curcumin as a novel pharmacological agent for the treatment, prevention, and/or diagnosis of other pathological conditions in human beings.

Chemistry of curcumin
Curcumin is a hydrophobic natural product that is composed of two phenolic rings, each substituted with a methoxy ether functionality in the ortho-position (Figure 1). The two phenolic rings are joined via an aliphatic unsaturated heptene linker in the para-position that also contains an α, β diketonic functionality on carbon-3 and -5. Various studies have indicated that the diketone functionality can undergo reversible tautomerization between enolic- and ketonic-forms. Tautomerization of curcumin occurs in a pH-dependent manner, with the bis-keto form predominating in acidic and neutral solutions, and the enol-form in alkaline solutions. While in the bis-keto form, carbon-4 of the heptene linker can function as an extremely powerful proton donor, while the enol form functions mainly as an electron donor, chemical activity that bestows upon curcumin its antioxidant properties. In fact, the antioxidant properties of curcumin are several times more potent than those exhibited by vitamin E. Commercially produced curcumin is composed of three major components, commonly referred to as the curcuminoids: curcumin I (described above), demethoxycurcumin (curcumin II; lacks one methoxy functionality), and bisdemethoxycurcumin (curcumin III; lacks both methoxy functionalities) (Figure 1).

Recent studies on curcumin pharmacokinetics
The pharmacokinetics of curcumin have been extensively studied in animals, and to a lesser extent in humans, and are reviewed thoroughly in Sharma et al. In summary, the vast majority of these studies have demonstrated that curcumin exhibits extremely poor gastrointestinal absorption/oral bioavailability, and undergoes metabolism to form several
chemical species, including curcumin glucuronide, curcumin sulfate, hexahydrocurcumin, tetrahydrocurcumin, and dihydrocurcumin. One of the major experimental initiatives in the field in recent years has been the development of curcumin derivatives, curcumin analogs, and curcumin-drug vehicle combinations that display enhanced absorption and systemic bioavailability as compared to the parent drug.

A group from Thailand recently synthesized succinyl derivatives of all three of the main curcuminoids. The hydrolysis of curcumin diethyl disuccinate in phosphate buffer (pH 7.4) and in human plasma followed pseudo first-order kinetics. The $k_{obs}$ and $t_{1/2}$ of this compound in phosphate buffer was significantly greater than that of curcumin, indicating greater chemical stability. The compound also demonstrated the ability to successfully release curcumin in human plasma. A Chinese study utilized reversed phase-high performance liquid chromatography to demonstrate that intravenous injection of a curcumin prodrug (curcumin didecanoate) provided sustained plasma levels of curcumin itself. A group in India investigated the effect of complexing curcumin with phosphatidylcholine (CU-PC) on curcumin pharmacokinetic parameters. Ex vivo studies using the everted intestine sac technique demonstrated that CU-PC displayed significantly greater absorption than curcumin alone. In vivo studies in rats and in vitro studies utilizing isolated rat hepatocytes revealed that CU-PC displayed enhanced bioavailability and pharmacokinetics, and significantly increased hepatoprotective activity compared to curcumin alone. Similarly, a group from the University of Athens, Greece, recently synthesized a stable curcumin formulation composed of egg-phosphatidylcholine (EPC) liposomes (drug to lipid molar ratio of 1:14) that demonstrated an $-14\%$ release of the compound in fetal bovine serum after 96 hours of incubation.

A recent randomized, double-blind, crossover clinical study investigated the effect of a phospholipid lecithin formulation of standardized curcuminoids (Meriva®) on relative absorption of the compounds. Meriva administration increased curcuminoid absorption 29-fold compared to an unformulated curcuminoid mixture, with demethoxycurcumin achieving the greatest absorption and systemic bioavailability. Only phase-2 metabolites of the curcuminoids could be detected. However, the curcuminoid concentration in plasma remained significantly lower than that required for inhibition of most of curcumin’s identified anti-inflammatory targets.

A Chinese laboratory synthesized a curcumin-loaded spherical core-shell structure nanoparticle composed of methoxy polyethylene glycol-poly (caprolactone) block copolymers (mPEG-PCL). Investigations revealed that curcumin was incorporated into mPEG-PCL nanoparticles with high encapsulation efficiency, could be released in a sustained manner, was efficiently transported into cells via endocytosis, and intracellularly localized primarily around nuclei. An Indian group formulated curcumin nanoparticles (nanocurcumin) that possess a narrow particle size distribution in the range of 2 to 40 nm, and was freely dispersible in water in the absence of surfactants. Wayne State University in the USA prepared a curcumin microparticle complex using poly(D,L-lactide-co-glycolide) polymer that displayed a 76% drug encapsulation efficiency. Curcumin release from these microparticles was sustained over a 4-week period in vitro, and a single subcutaneous injection in mice sustained curcumin concentration in the liver for $-1$ month. A group from Louisiana State University in the USA synthesized a nanoparticle complex consisting of curcumin and rubusoside. The aqueous solubility of curcumin dramatically increased in the presence of rubusoside, remained stable in physiological conditions, did not precipitate out of solution upon dilution, and demonstrated efficacy against human colon, breast, and pancreatic cancer cells in vitro. A group from Chulalongkorn University in Thailand recently synthesized a curcumin loaded monoplymeric nanosphere (ethylcellulose; C-EC) and a curcumin loaded dipolymere nanosphere (methylcellulose and ethylcellulose; C-ECMC) that both adhered to stomach mucosal epithelial cells (as revealed by scanning electron microscopy). A curcumin implant utilizing poly (epsion-caprolactone) as a polymeric matrix, released curcumin in a biphasic release pattern with Higuchi kinetics (1.8 times greater release in vivo than in vitro). Approximately 60 ± 20 ng/g curcumin was found in the liver of test animals 4 days after implantation and remained constant at 8–15 ng/g for up to 35 days.

A recent study conducted in China demonstrated that application of Gelucire 44/14 with curcumin increased the apparent permeability coefficient of curcumin 1.86-fold across excised rabbit cornea, and promoted curcumin ocular bioavailability as evidenced by a 1.77-fold maximal increase in the area under the curve for the compound. A Taiwanese group also recently synthesized a eucalyptol microemulsion vehicle (eucalyptol, polysorbate 80, ethanol, water) for transdermal delivery of curcumin that increased the percutaneous permeation rate of the compound 15.7-fold compared to the use of formulations with eucalyptol only. A recent study elucidated a unique mechanism of curcumin metabolism by purifying an enzyme from Escherichia coli isolated from human feces. CurA (also known as NADPH-dependent
curcumin/dihydrocurcumin reductase) metabolized curcumin in a two-step reduction process that produced dihydrocurcumin as an intermediate and tetrahydrocurcumin as the end product.57

**Recent studies on curcumin: pharmacodynamics and clinical pharmacology mechanisms of action, pharmacological effects, and potential clinical applications**

**Antimicrobial and antiviral effects**

Several recent studies have highlighted the potential usefulness of curcumin as an antimicrobial and antiviral agent. Nanocurcumin (described above) displayed much greater aqueous dispersion than curcumin against *Staphylococcus aureus, Bacillus subtilis, E. coli, Pseudomonas aeruginosa, Penicillium notatum,* and *Aspergillus niger.*50 Nanocurcumin displayed very effective antibacterial activity and transmission electron microscopy analysis revealed that nanocurcumin particles effectively broke bacterial cell walls, inducing a bactericidal effect.50 Curcumin demonstrated antimicrobial action against *Helicobacter pylori* infection in mice via downregulation of matrix metalloproteinase-3 (MMP-3) and MMP-9 expression.54 Curcumin demonstrated antifungal activities against 14 strains of *Candida* in vitro.59 In the cases of *C. albicans* and *C. glabrata,* curcumin significantly inhibited fungal cell H+ extrusion in the absence/presence of glucose, decreased ergosterol content of the fungal cell membrane, and decreased proteinase secretion from the fungal cells, though these effects were not as potent as those exhibited by the antifungal azole fluconazole.59

Curcumin suppressed HIV-1 replication pathways by blocking transactivator of transcription (Tat)-induced long terminal region (LTR) transactivation.60 Specifically, curcumin reversed Tat-mediated downregulation of histone deacetylase 1 (HDAC1) expression, Tat-mediated dissociation of HDAC1 from LTR, and p65/NF-κB binding to LTR promoters.60 Curcumin also blocked Tat-induced phosphorylation of p65 and IκB kinase, as well as Tat-mediated downregulation of AMP-activated protein kinase and acetyl-CoA carboxylase activity.60 Biophysical studies revealed that curcumin effectively interacts with the HIV reverse transcriptase enzyme.61 Curcumin and two of its derivatives, gallium-curcumin and copper-curcumin, potently inhibited the replication of herpes simplex virus-1 in vitro.62

**Inflammation and immunity**

Curcumin has long been touted as a powerful anti-inflammatory and immunomodulatory agent, and recent studies continue to confirm that fact. Curcumin treatment of human intestinal microvascular endothelial cells (HIMEC) in vitro suppressed tumor necrosis factor-alpha (TNF-α)/lipopolysaccharide (LPS)-induced vascular cell adhesion molecule-1 (VCAM-1) expression; inhibited Akt/mitogen-activated protein kinase (MAPK)/NF-κB pathways; and attenuated leukocyte adhesion to TNF-α/LPS-activated HIMEC monolayers under physiological shear stress conditions.60 Curcumin successfully attenuated the transcriptional and translational expression of intracellular cell adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), and interleukin (IL)-8 in TNF-α-stimulated human umbilical vein endothelial cells, resulting in decreased monocyte adhesion (among other effects).64 An Indian study demonstrated that dietary curcumin exerted a protective effect in mice against endotoxin shock by inhibiting neutrophil transmigration and infiltration from the vasculature into the liver of LPS-injected animals.65 This pharmacological effect was correlated molecularly with significant blockade of ICAM-1 and VCAM-1 expression in liver and lungs.65 This improved survival and reduced severity of lethargy, diarrhea, and watery eyes in cases of high-dose endotoxin shock.65

An 8-month human study conducted in 100 osteoarthritis patients demonstrated that treatment with Meriva significantly improved clinical (WOMAC score, Karnofsky Performance Scale Index, treadmill walking performance) and biochemical (IL-1β, IL-6, soluble CD40 ligand, soluble vascular cell adhesion molecule, erythrocyte sedimentation rate) end points compared to the control group of patients.66 An in vivo and in vitro study in mice and cultured renal tubular epithelial cells demonstrated that curcumin was a potent protective agent against LPS-induced renal inflammation.67 Specifically, curcumin downregulated LPS-mediated expression of renal MCP-1 at the transcriptional level; inhibited transcription of MCP-1 and IL-2 in cultured cells; partially attenuated the secretion of MCP-1 and IL-8; and inhibited NF-κB DNA-binding.57 Curcumin functions as a potent anti-inflammatory agent in periodontal disease.58,68 While demonstrating no appreciable effect on alveolar bone resorption or p38 MAPK function, curcumin treatment appeared to effectively inhibit transcriptional and translational expression of pro-inflammatory cytokines and dose-dependently attenuated NF-κB activation in the gingival tissue of rats suffering from experimental periodontal disease.68,69 Curcumin significantly reduced
inflammatory infiltrate, increased the collagen content, and increased fibroblastic cell numbers in gingival tissues. PEGylated curcumin analogs demonstrated the ability to more powerfully induce the expression and transcription factor activity of the antioxidant defense system regulator nuclear factor (erythroid-derived)-like 2 (Nrf2) more potently than free curcumin in a luciferase-based reporter assay. Paradoxically, an in vitro study recently demonstrated that curcumin promoted prostanoioid production in the presence of exogenous arachidonic acid by stimulating the expression of COX-2, prostaglandin I2 synthase (PGI2S), and membrane-associated prostaglandin E synthase-1 (mPGES-1) at the transcriptional level in human coronary artery endothelial cells.

An in vivo study in rats revealed that orally administered curcumin, in combination with the compounds myrcene and cineol, exerted immunomodulatory effects in cases of exposure to the persistent environmental pollutant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Specifically, the curcumin-myrcene-cineol combination reduced TCDD-stimulated CD8+ lymphocyte counts, while significantly increasing CD3+, CD4+, CD161+, CD45RA, and CD4+CD25+ lymphocyte counts. This combination of agents also upregulated the antioxidant defense system in rats exposed to TCDD, protecting the liver from oxidative stress. In vitro studies using mouse CD4+ T-lymphocytes demonstrated that curcumin exerts some of its immunomodulatory effects by suppressing IL-2, forkhead box P3 (Foxp3), and CD25 expression; inhibiting IL-2 receptor (IL-2R)-mediated phosphorylation of signal transducer and activator of transcription 5A and janus kinase 3; and downregulating the suppressor function of CD4+CD25+ regulatory T-cells. Another study revealed that the polyphenolic compound was able to inhibit store-operated Ca2+ entry through inhibition of calcium release activated calcium current (ICrAC) in lymphocytes in vitro. Curcumin also demonstrated the ability to inhibit delayed rectifier potassium current (IKr) and ISkA75.

**The cardiovascular system**

In recent years, there has been a growing interest in the potential pharmacological effects (particularly protective effects) of curcumin in the cardiovascular system. A study conducted in Romania demonstrated that curcumin was able to reverse the pro-inflammatory action of the cytokine resistin in human endothelial cells. Curcumin, and an extract prepared from *Morus alba* leaves, inhibited P-selectin and fractalkine expression; reduced nicotinamide adenine dinucleotide phosphate (NADPH) activation and monocyte adhesion to human endothelial cells; and prevented an increase in intracellular ROS levels. In light of the fact that all of these events are regulated by resistin, these results suggest that curcumin may represent a novel therapeutic agent in resistin-mediated vascular pathologies. Curcumin-mediated inhibition of CREB-binding protein (CBP)/p300 disrupted hypoxia-inducible factor-1α-mediated expression of pro-angiogenic genes in human lung microvascular endothelial cells, including platelet-derived growth factor, vascular endothelial growth factor (VEGF), placental growth factor, and plasminogen activator inhibitor-1. Dietarily administered curcumin and tetrahydrocurcumin were both able to prevent L-Nω-nitroarginine methyl ester-induced vascular dysfunction and hypertension in rats. Specifically, curcumin and tetrahydrocurcumin were able to suppress blood pressure elevation, decrease vascular resistance, and restore vascular responsiveness, and these pharmacological effects appeared to be mediated through suppression of endothelial nitric oxide synthase expression in aortic tissue and plasma nitrate/nitrite ratios. Both compounds also functioned as antioxidants, by reducing vascular superoxide production, decreasing oxidative stress, and increasing glutathione levels. Curcumin exerts protective antioxidant effects on blood platelets in vitro by inhibiting peroxynitrite-mediated carbonylation of blood plasma and platelet proteins, partially preventing 3-nitrotyrosine formation in plasma proteins, and inhibiting thiobarbituric acid reactive substance generation in platelets and blood plasma.

A study out of the University of Illinois in the USA demonstrated that curcumin dose-dependently prevented copper sulfate-mediated oxidation of low-density lipoproteins (LDL) in vitro, an event that is associated with thrombosis and atherosclerosis. A study conducted in Taiwan revealed that curcumin efficiently inhibited TNF-α-mediated migration of human aortic smooth muscle cells in vitro (an event also associated with atherosclerosis), and that these results were correlated with a downregulation of MMP-9 expression/activity, ROS production, and NF-κB nuclear translocation. Four-month administration of 20 mg/kg·day curcumin to apolipoprotein E knockout mice (apoE−/−) resulted in a 50% reduction in the number of atherosclerotic lesions and a 5-fold increase in caveolin-1 expression. In oxidized-LDL-treated rat vascular smooth muscle cells in vitro, curcumin significantly diminished cellular lipid droplet number and area; downregulated levels of total cholesterol, cholesterol ester, and free cholesterol; elevated expression of caveolin-1; and inhibited sterol response element binding
Cancer

Of all the possible clinical applications of curcumin, none has garnered more interest and investment of research resources and manpower than the potential use of curcumin as a cancer chemopreventative and chemotherapeutic agent. This interest and this voluminous amount of investigations continue unabated. One anticancer aspect of curcumin that has attracted heightened attention in the past several years is the anti-angiogenic potential of the compound.87,88Treatment with curcumin alone or in combination with the chemotherapeutic agent carboplatin caused a significant reduction in microvessel density, the plasma concentration of VEGF, and the percentage of fetal liver kinase-1 (Flk-1)-reduction in microvessel density, the plasma concentration of VEGF, and the percentage of fetal liver kinase-1 (Flk-1)-rich tumors in an in vivo Ehrlich ascites carcinoma murine model, suggesting that curcumin displays anti-angiogenic potential.89 Curcumin significantly inhibited the growth, survival, migration/invasion, and angiogenic potential of adenoid cystic carcinoma cells in vitro and in vivo, and these effects of curcumin were correlated with downregulation of VEGF and MMP-2/9, and the inhibition of the mTOR and NF-κB pathways.90 In vivo, curcumin significantly reduced the emergence of Opisthorchis viverrini- and N-nitrosodimethylamine-induced cholangiocarcinoma in hamsters through a variety of mechanisms, including the inhibition of angiogenesis as evidenced by decreased translational expression of VEGF and microvessel density.91 Subcutaneous injection of curcumin microparticles synthesized from poly(D,L-lactide-co-glycolide) inhibited VEGF expression and disrupted tumor microvessel development in nude mice bearing human breast adenocarcinoma cell xenografts.92 A Korean study demonstrated that curcumin inhibited IL-2-mediated induction of inducible NOS expression and nitric oxide production, and stimulated the proliferation, survival, and cytotoxic action of lymphocytes and macrophages during IL-2 stimulation in a mouse actes tumor model.93 Curcumin effectively disrupts the physical and functional interactions between integrin α6β4 and EGFR, leading to inhibition of integrin α6β4 and EGFR-dependent functions in carcinoma cells.94 Curcumin was also able to block EGF-mediated mobilization of integrin α6β4 to the leading edges of migrating cells (both lamellipodia and filopodia) suggesting a possible mechanism for the compound’s antimotility and anti-invasion action against breast carcinoma cells.94 A proteomic study revealed that curcumin-mediated induction of human breast cancer cell apoptosis in vitro correlated with major changes in translational expression of 12 proteins, including downregulation of transactivation response DNA-binding protein-43, splicing factor 2/alternative splicing factor, and eukaryotic initiation factor 3i, and upregulation of 3-phosphoglycerate dehydrogenase, endoplasmic reticulum protein 29, and platelet-activating factor acetylhydrolase IB subunit β.95 In addition, C-EC and C-ECMC nanospheres demonstrated free radical scavenging ability and exerted cytotoxic effects against human breast cancer cells and human hepatoblastoma cells in vitro.93 Curcumin demonstrates synergy with the chemotherapeutic agent paclitaxel against cervical cancer in vivo and in vitro.96 Combination therapy with curcumin and paclitaxel in mice synergistically reduced tumor incidence and tumor volume, and this was correlated with curcumin-mediated downregulation of the NF-κB, Akt, and MAPK pathways.96 Pre-exposure of cervical cancer cells to curcumin in vitro potently potentiated paclitaxel-mediated apoptosis.96 Curcumin inhibited cell growth, proliferation, and survival of human cholangiocarcinoma cells in vitro by abolishing activation of NF-κB; suppressing activation of STAT3; inducing expression of peroxisome proliferator-activated receptor gamma (PPAR-γ) and the death receptors DR4 and DR5; inhibiting the Akt pathway; and downregulating the expression of numerous pro-cell survival and pro-cell proliferation proteins.97 EPC liposomal curcumin (described earlier) demonstrated greater cytotoxic effect against multidrug resistance-phenotypic human colon cancer cell lines than free curcumin did,47 while curcumin succinate produgs (described earlier) displayed IC50 values of 1.8–9.6 μM against colon cancer cells in vitro.44 Curcumin induced autophagic-mediated death in human colon cancer...
cells by functioning as a pro-oxidant, as treatment with N-acetylcysteine (NAC), an antioxidant and ROS scavenger, prevented this occurrence. Another study supported these findings by demonstrating that curcumin-mediated suppression of E2F4 expression in human colon cancer cells was mediated by ROS production, as treatment with NAC reversed this phenomenon.

In a recent open-label, nonrandomized, Phase IIa clinical trial, 41 patients meeting specific criteria were given oral curcumin (2 g or 4 g day) for 30 days. Patients receiving either dose showed no significant decrease in the levels of the pro-carcinogenic COX-1/2-produced eicosanoids PGE$_2$ and 5-hydroxyeicosatetraenoic acid in either aberrant crypt foci (ACF) or normal mucosa. The group receiving 4 g/day did show a 40% reduction in the number of ACF, and this was correlated with a five-fold increase in posttreatment curcumin/conjugate plasma concentration. A human study conducted in China revealed that curcumin administration to colorectal cancer patients increased patient body weight, decreased TNF-α serum concentration, increased tumor cell apoptosis, and enhanced expression of p53 in tumor tissue. mPEG-PCL-based curcumin-loaded nanoparticles (described earlier) showed dose-dependent cytotoxicity in vitro against rat glioma cells. Intravenous administration of mPEG-PCL curcumin micelles more potently inhibited tumor cell-induced angiogenesis and colon carcinoma cell growth in vivo than did free curcumin. Curcumin significantly inhibited the proliferation of human leiomyosarcoma cells through inhibition of the mTOR pathway, as rapamycin exerted the same effect, though curcumin, but not rapamycin, stimulated apoptosis of these same cells in a concentration-dependent manner. Curcumin induced caspase-3 and -8-dependent apoptosis in human liposarcoma cells in vitro and in vivo by inducing endoplasmic reticulum stress via inhibition of the function of sarkosomal/endoplasmic reticulum Ca$^{2+}$-ATPase 2 in a dose-dependent manner.

Administration of a nanoparticle-encapsulated curcumin formulation induced G$_1$/M cell cycle arrest and apoptosis, and decreased anchorage-independent clonogenic growth of human medulloblastoma and glioblastoma cell lines in vitro. These pharmacological effects were correlated with downregulation of the insulin-like growth factor pathway, attenuation of STAT3 levels, and inhibition of Hedgehog signaling. A recent study revealed that curcumin is able to attenuate ionizing radiation-induced NF-κB activity, and telomerase and human telomerase reverse transcriptase transcriptional expression in human neuroblastoma cells. Curcumin demonstrated synergy with arabinoxylan rice bran to inhibit the proliferation, induce G$_2$-$G_1$ arrest, and modulated the expression of Bcl-2 family members to favor apoptosis induction in human multiple myeloma cells in vitro. Curcumin reversed resistance to the topoisomerase I inhibitor irinotecan in nonsmall lung cancer cells, through disruption of the NF-κB pathway. Curcumin significantly reduced the viability of human oral cancer cells in vitro via downregulation of Notch-1 and NF-κB, and inhibited the proliferation and invasiveness of human tongue squamous cell carcinoma cells, by dramatically altering their genetic profile, influencing the activity of 280+ genes. A study in Spain revealed that curcumin inhibited the in vitro viability of human oral squamous cell carcinoma cells, and that it worked synergistically with irradiation to more potently inhibit that viability.

A chemopreventive study revealed that curcumin dramatically disrupted wingless (Wnt)/β-catenin signaling pathway-mediated transcriptional activity in human androgen-dependent prostate cancer cells, but not in human androgen-independent prostate cancer cells. This disruption was the result of curcumin-mediated downregulation of transcription factor-4, CBP, and p300 protein levels, and resulted in G$_1$ cell cycle arrest. Curcumin treatment of human pancreatic cancer cell tumor xenografts significantly reduced in tumor volume and angiogenic potential. Curcumin successfully inhibited cellular proliferation by inducing G2-M arrest and inducing apoptosis, and these effects correlated with increased phosphorylation of Chk2, increased expression of cyclin B1 and cell division cycle-2. Interestingly, curcumin stimulated the transcriptional expression of COX-2 and VEGF, but no corresponding increase in protein levels was seen. It was observed that curcumin stimulated the expression of the RNA binding proteins CUGBP2/CEL2F2 and TIA-1, and increased the association of CUGBP2 with COX-2 and VEGF mRNA, leading to a significant increase in their half-lives.

The central nervous system
Much attention has been placed on the neuroprotective and neurotherapeutic potential of curcumin in recent years. A Chinese study investigated the potential of curcumin as a therapeutic agent in Alzheimer’s disease in vitro. In human neuroblastoma cells, curcumin dose- and time-dependently decreased the transcriptional and translational expression of glycogen synthase kinase-3 beta, increased the transcriptional and translational expression of β-catenin and cyclin D1, and stimulated β-catenin nuclear translocation, suggesting that curcumin activates the Wnt/β-catenin signaling
pathway. A recent Japanese study strongly suggests that curcumin may bind directly to amyloid-β (Aβ) oligomers and fibrils, especially to globulomer and Aβ-derived diffusible ligand (ADDL). A chemical entity composed of a [M(CO)3]4- (M = Re, 99mTc) core with curcumin bound to it as a bidentate OO ligand was recently synthesized. This complex demonstrated strong binding to β-amyloid plaques, indicating that this chemical entity could be utilized as a radioimaging probe, particularly in cases of Alzheimer’s disease.

A Chinese study investigated the potential antidepressive action of curcumin utilizing the exogenous corticosterone (CORT) administration-induced model of depression in rats. Curcumin therapy significantly reversed depression-like behavior induced by CORT (as evidenced by rat sucrose consumption and performance of the forced swim test), and this appeared to be mechanistically linked to curcumin-mediated restoration of brain-derived neurotrophic factor (BDNF). The anti-epileptic potential of curcumin was revealed in mice, as oral administration of the polyphenol dose-dependently suppressed pentyleneetrazole-induced kindling, and reduced malondialdehyde and glutathione levels in murine brain tissues. Curcumin dose-dependently protected PC12 cells in vitro from A53T alpha-synuclein toxicity by enhancing expression of the regulated upon activation, normal T-cell expressed, and secreted (RANTES) via activation of the phosphatidylinositol-3 kinase (PI3K) and MAPK signaling pathways.

Curcumin administration increased the resolution of hematomas in a murine model of intracerebral hemorrhage (ICH). This pharmacological effect was associated with curcumin-mediated downregulation of pro-inflammatory mediators (TNF-α, IL-6, IL-1β), reduction of blood–brain barrier disruption, and attenuation of vasogenic edema. These pharmacological actions also resulted in a significant improvement in neurological outcome scores in ICH mice. Orally administered curcumin exerted a strong protective effect in rats who suffered from spinal cord injury via its antioxidant potential. Specifically, curcumin treatment significantly increased the concentration of superoxide dismutase and decreased the concentration of malondialdehyde in the serum. Curcumin also exerted a protective and therapeutic effect in the CNS following sciatic nerve crush (SNC). In rats experiencing SNC, curcumin treatment reduced the loss of A- and B-cell volume and number, reduced the loss of satellite cell number, and significantly improved motor function.

**Diabetes**

Because of the increasing evidence that the pathogenesis of type 2 diabetes mellitus (T2DM) and obesity is connected to inflammation, curcumin has emerged as a potential drug of interest for diabetic and obesity pharmacology. A recent Egyptian study investigated the potential of curcumin as a therapeutic agent for the treatment of diabetes in vivo. Mice suffering with experimental diabetes were administered 10 mM curcumin intraperitoneally for 28 days in combination with or without a single bone marrow transplantation. Curcumin treatment significantly reversed streptozotocin-induced hyperglycemia, glucose intolerance, hypoinsulinemia, and pancreatic islet damage; attenuated pancreatic lipid peroxidation; upregulated antioxidant enzyme activity; and suppressed serum levels of TNF-α and IL-1β. A 16-week in vivo study revealed that curcumin treatment significantly reduced the induction of diabetic retinopathy in rats. Specifically, curcumin showed significant hypoglycemic activity; positively modulated activity of antioxidant enzymes and molecules; reduced retinal levels of pro-inflammatory cytokines, TNF-α, and VEGF; and prevented endothelial cell organelle degeneration and the thickening of capillary basement membranes in the retina.

Another Egyptian study investigated the possibility of curcumin use in the therapy of T2DM. Fifteen days of oral administration of curcumin to rats fed with a high fat diet for 60 to 75 days demonstrated an anti-hyperglycemic effect/improved insulin sensitivity and an anti-lipolytic effect, by attenuating TNF-α levels and plasma free fatty acid levels, respectively. Curcumin treatment of hepatic stellate cells (HSC) prevented high level glucose-induced cell proliferation, type I collagen production, expression of HSC-activating genes, and HSC intracellular glucose levels. Curcumin also abrogated glucose transporter 2 (GLUT2) membrane translocation via inhibition of p38 MAPK signaling, and reduced GLUT2 expression by activation of PPAR-γ and de novo glutathione synthesis. Finally, a Thai study demonstrated the potential for use of curcumin as an antiangiogenic agent in the therapy of diabetes mellitus as treatment of diabetic mice with curcumin (60 mg/kg body weight) over a 4- to 8-week period resulted in a significant reduction in the
expression of VEGF in renal tissue. Curcumin functions as a potent irreversible inhibitor of fatty acid synthase (FAS) in 3T3-L1 cells, a mechanism that resulted in a decrease of FAS, PPAR-γ, and CD36 expression, and in the inhibition of cellular differentiation and lipid accumulation. A curcumin–polyethylene glycol conjugate (CCM–PEG) sensitized preadipocytes to the cytotoxic effect of curcumin and improved curcumin-mediated inhibition of adipocyte differentiation.

The renal system

A recent Egyptian study demonstrated that pretreatment with curcumin exerted protective effects in rats subjected to acute renal injury (renal ischemia followed by reperfusion). Oral administration of curcumin significantly reduced the plasma levels of numerous cytokines following acute renal injury, specifically TNF-α, IL-1β, IL-12, IL-18, and interferon-gamma (IFN-γ). Curcumin also reduced apoptosis induction in renal and pulmonary tissue by inhibiting transforming growth factor-beta (TGF-β) and caspase-3. A study conducted in the Netherlands investigated the potential use of curcumin as a therapy for autosomal dominant polycystic kidney disease (ADPKD) in vivo. Curcumin-treated mice carrying a ADPKD-associated gene deletion displayed improved renal histology, and reduced proliferation index, cystic index, and kidney weight/body weight ratios. Biochemically, these results correlated with curcumin-mediated inhibition of the mTOR and STAT3 pathways. Curcumin also significantly decreased the production of the pro-inflammatory cytokines IL-6 and IL-1β by peripheral blood mononuclear cells isolated from human patients suffering from chronic kidney disease.

The respiratory system

An in vivo study in rats demonstrated that pretreatment with curcumin exerted a potent protective effect on the lungs following cardiopulmonary bypass (CPB). Specifically, curcumin pretreatment reduced plasma, bronchoalveolar lavage fluid, and lung tissue concentrations of IL-8, TNF-α, and MMP-9 caused by CPB. Curcumin also downregulated lung tissue expression of toll-like receptor 4, myeloid differentiation primary response gene 88, and NF-κB, and significantly reduced the lung injury score of the treated rats. In vitro, curcumin, in combination with maximal doses of genistein, was able to potentiate the channel activity of cystic fibrosis transmembrane conductance regulator (CFTR) bearing the G551D mutation up to 50% of the function of the wild type CFTR. Co-application of curcumin and genistein over a lower concentration range was also able to rescue the gating defect of G551D-CFTR synergistically.

Other body systems

A recent study demonstrated a possible mechanism for the usefulness of curcumin as an agent for the treatment of gastrointestinal disorders such as diarrhea, abdominal cramps, and irritable bowel syndrome. Intragastric administration of a single dose of curcumin to rats significantly decreased the distance traveled by barium sulfate in the small intestine, suggesting that curcumin effectively suppressed intestinal motility. In the integumentary system, an in vitro study demonstrated that curcumin modulates wound healing biphasically, with low doses (1–5 μM) stimulating this homeostatic process, and high doses inhibiting it. This study suggests that curcumin functions as a hormetin by inducing stress response pathways such as Nrf2 and heme oxygenase-1 (HO-1). In one of the first studies investigating the effect of curcumin on the reproductive system, it was discovered that curcumin dose-dependently inhibited the forward motility of both murine and human sperm, the capacitation/acrosome reaction, and murine fertilization in vitro. Intravaginal administration of curcumin in mice also caused a significant reduction in fertility. Another study demonstrated that intragastrically administered curcumin exerted anti-angiogenic activity in a rat model of endometriosis by significantly reducing heterotopic endometrial microvessel quantity and VEGF translational expression.

Toxicology

The vast majority of preclinical and clinical studies utilizing curcumin have yet to reveal any significant toxicity associated with the compound. In fact, many recent studies suggest that curcumin itself may be a potent anti-toxicological agent against drugs and other toxic compounds. A study conducted in rats demonstrated that pretreatment with curcumin (both single dose and multiple doses) was able to prevent the methemoglobinemia associated with exposure to the antimycobacterial drug dapsone. Curcumin is able to significantly reduce the incidence of abnormal oro-facial movements in rats treated with the dopamine D2 receptor antagonist haloperidol, and a proteomic analysis revealed that this effect was correlated with an increase in the translational expression of Bcl-xL. A recent study demonstrated that curcumin may exert chemopreventative potential in cases of oxidative/nitrative stress following praziquantel treatment of liver fluke infections. Curcumin administered to Opisthorchis viverrini-infected, praziquantel-treated hamsters
A human study conducted in India suggests that curcumin may exert significant preventative effects against arsenic-induced carcinogenesis.\(^{147}\) Asymptomatic, chronically arsenic-exposed volunteers (n = 66) treated with curcumin showed significant reductions in 8-hydroxy-2′-deoxyguanosine levels and oxoguanine glycosylase expression, both of which are upregulated by arsenic.\(^{147}\) Curcumin treatment also induced the transcriptional and translational expression of DNA repair enzymes involved in the base excision repair and nonhomologous end-joining pathways.\(^{147}\) The presence of curcumin exerted protective effects in larvae of Drosophila melanogaster against the potential industrial and household toxins benzene, toluene, and xylene.\(^{148}\) Specifically, curcumin reduced cytochrome P450 activity, GST levels, oxidative stress parameters, and genotoxic and apoptotic endpoints caused by exposure to these compounds.\(^{148}\)

An in vivo study investigating the protective effects of curcumin against lead-induced cardiotoxicity in rats, indicated that intraperitoneal administration of curcumin alone, or in conjunction with exercise, was able to lower lead-induced levels of high sensitivity-C reactive protein, creatine kinase-MB, malondialdehyde, and LDL, while simultaneously increasing glutathione peroxidase, TAC, and high-density lipoprotein levels.\(^{149}\) Curcumin pretreatment of human embryo lung fibroblast cells prevented cell cycle changes induced by the occupational toxin silica by down-regulation of E2F-4 and overexpression of cyclin D1 and cyclin-dependent kinase 4.\(^{150}\)

An in vivo study revealed that curcumin could successfully suppress selenium-induced cataractogenesis in rats by inhibiting selenium-mediated upregulation of αA-crystallin, αB-crystallin, and heat shock protein 90 expression.\(^{151}\)

**Conclusion**

The field of inquiry into the pharmacological properties and applications of curcumin is a rapidly growing, progressing, and expanding enterprise, as evidenced by the studies reviewed above and the many more being reported every day. The pharmacokinetic parameters of the parent drug remain a significant challenge to widespread clinical use of curcumin for the treatment of many human diseases, but a tremendous amount of promising work is being conducted to circumvent this problem through the utilization of unique delivery systems and chemical modifications. This work may also tremendously benefit the field of curcumin study by producing patentable drug constructs that could tweak the curiosity of well-funded and well-resourced pharmaceutical companies worldwide to seriously consider developing and producing curcumin as a drug. The above reviewed studies, as well as many more not described in this work, suggest that the potential clinical application of curcumin is extremely vast, owing to its diverse and potent array of pharmacological effects in almost all of the major organ systems of the human body. These effects are supported by an equally vast amount of molecular targets and mechanisms of action displayed by the compound in a large host of cell types both in vitro and in vivo. Coupled with the fact that preliminary studies suggest that the polyphenol is relatively safe for human administration, curcumin’s diverse molecular targeting capability may make it a true “go-to” agent for the prevention and therapy of numerous human pathological conditions, particularly inflammatory-based processes, and, perhaps most importantly, cancer. Hippocrates is famous for once saying, “Let food be thy medicine and medicine be thy food.” Curcumin may indeed be the medicine and the food that the world has long been looking for.

**Acknowledgments**

The authors’ work cited in this review was supported in part by the NIH (CA115414 to SH) and the American Cancer Society (RSG-08-135-01-CNE to SH).

**Disclosure**

No conflicts of interest were declared in relation to this paper.

**References**


